Imipramine

Research summary

Scientific evidence for imipramine centers on its efficacy in treating chronic and major depression, with double-blind trials demonstrating significant reductions in depressive symptoms, global illness severity, and improvements in self-rated functioning compared to placebo. Favorable responses occur in a substantial portion of treated patients, particularly those with moderate severity and prolonged symptom duration. However, research specifically in healthy human subjects is absent, limiting direct applicability to non-clinical populations; available data derive from individuals with diagnosed depressive disorders. Consensus supports imipramine as an effective option for previously undertreated chronic depressions, though its narrow therapeutic index necessitates careful monitoring to balance benefits against side effects. No studies were identified examining benefits or effects in healthy humans without depressive symptoms.